Home > Research > Publications & Outputs > Peak plasma interleukin-6 and other peripheral ...

Links

Text available via DOI:

View graph of relations

Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published
  • Craig J. Smith
  • Hedley C. A. Emsley
  • Carole M. Gavin
  • Rachel F. Georgiou
  • Andy Vail
  • Elisa M. Barberan
  • Gregory J. del Zoppo
  • John M. Hallenbeck
  • Nancy J. Rothwell
  • Stephen J. Hopkins
  • Pippa J. Tyrrell
Close
Article number2
<mark>Journal publication date</mark>15/01/2004
<mark>Journal</mark>BMC Neurology
Volume4
Publication StatusPublished
<mark>Original language</mark>English

Abstract

Background: Cerebral ischaemia initiates an inflammatory response in the brain and periphery. We assessed the relationship between peak values of plasma interleukin-6 (IL-6) in the first week after ischaemic stroke, with measures of stroke severity and outcome. Methods: Thirty-seven patients with ischaemic stroke were prospectively recruited. Plasma IL-6, and other markers of peripheral inflammation, were measured at pre-determined timepoints in the first week after stroke onset. Primary analyses were the association between peak plasma IL-6 concentration with both modified Rankin score (mRS) at 3 months and computed tomography (CT) brain infarct volume. Results: Peak plasma IL-6 concentration correlated significantly (p <0.001) with CT brain infarct volume (r = 0.75) and mRS at 3 months (r = 0.72). It correlated similarly with clinical outcome at 12 months or stroke severity. Strong associations were also noted between either peak plasma Creactive protein (CRP) concentration or white blood cell (WBC) count, and all outcome measures. Conclusions: These data provide evidence that the magnitude of the peripheral inflammatory response is related to the severity of acute ischaemic stroke, and clinical outcome.